In vivo antitumor effects of polyethylene glycol--modified recombinant human interleukin-2 on mouse uterine cervical carcinoma
Wang, L.; Wu, Y.; Zhang, Y.
Zhonghua Zhong Liu Za Zhi 18(4): 253-255
1996
ISSN/ISBN: 0253-3766 PMID: 9387313 Document Number: 457624
Polyethylene glycol (PEG-8000) -modified recombinant human interleukin-2 (PEG-rIL-2) is a cytokine with prolonged circulatory half-life. In this paper, the antitumor effects of PEG-rIL-2 against mouse uterine cervical carcinoma (U-14) transplanted intraperitoneally or subcutaneously is reported. PEG-rIL-2 at different doses was administered intratumorally. The results showed that PEG-rIL-2 (4 500IU, ip., QD times 5) prolonged survival time of mice bearing ascites tumor as compared to rIL-2 (P lt 0.01), but PEG-rIL-2 at lower doses was without therapeutic effect. In addition, compared to rIL-2, PEG-rIL-2 at different doses (1 500 apprx 13 500IU, QD times 5 ) caused significant dose-dependent growth inhibition of solid tumor (P lt 0.01) when the treatment started on lay 4 after subcutaneous inoculation of tumor.